Comparing two immune globulin treatments for CIDP
Part of Brain & nervous system, Immune system & allergy clinical trials.
This study tests if TAK-881 is as safe and effective as HYQVIA for adults with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). You may join if you have been stable on immune globulin therapy and have certain disability levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of CIDP by a nerve specialist.
- Your CIDP symptoms have improved with immune globulin treatment in the past.
- You are currently on a stable dose of immune globulin (IV or under-the-skin) for at least 12 weeks.
- You have a disability score between 0 and 7 on a standard CIDP scale.
- If you could become pregnant, you must use effective birth control and have a negative pregnancy test.
- You do not have other nerve diseases, serious infections, or uncontrolled heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new investigational drug called TAK-411 for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). It is for people who have already responded to immunoglobulin therapy and are on a stable dose.
This study looks at how well HyQvia works for adults with CIDP in everyday medical practice. It includes people who are already using HyQvia or are switching to it.
This study tests whether two different dose levels of Privigen (a type of immune blood treatment) are safe and effective for children and teens with CIDP. It may help improve nerve-related symptoms in people whose CIDP has been confirmed or is being evaluated as likely.
This study tests a new intravenous immunoglobulin (IVIG) treatment called KIg10 (QIVIGY) for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It aims to see if this treatment can help manage symptoms and maintain stability.
This study tests whether giving immune globulin under the skin (SCIG) can help people with newly diagnosed CIDP. It may help improve muscle strength and nerve symptoms while avoiding the need for earlier IVIG/SCIG treatment.
This Phase 1 study compares IVIG given through an IV versus SCIG given under the skin, for people with CIDP. It aims to find the right weekly SCIG dose based on your current IVIG dose, which could make treatment more convenient.
Hear when a new Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.